✨ Free AI Report
Cognition Therapeutics Inc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cognition Therapeutics Inc
Company Research

Cognition Therapeutics Inc: Business Overview, Financials & Competitive Analysis

Cognition Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and neurocognitive disorders, headquartered in Pittsburgh, Pennsylvania and foun...

Analyst-debate audio for Cognition Therapeutics Inc

AskCyborg analysts argue the bull and bear cases for Cognition Therapeutics Inc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Well-funded clinical-stage biotech with a differentiated lead candidate in a high-unmet-need indication; success depends on Phase...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cognition Therapeutics Inc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cognition Therapeutics Inc Overview

Pro stress-test →

Cognition Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and neurocognitive disorders, headquartered in Pittsburgh, Pennsylvania and founded in 2007. The company focuses on addressing unmet medical needs in diseases such as Alzheimer's disease, Parkinson's disease, and other central nervous system disorders.

Strategic Profile

Pro stress-test →

The company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease. Following strong phase II results, the company is prioritizing zervimesine for DLB psychosis with registrational trial planning underway, and its cash runway extends through Q2 2027, with START trial results expected in 2027.

Competitive Landscape

Pro stress-test →

Cognition Therapeutics develops small-molecule therapeutics aimed at treating age-related degenerative diseases and disorders of the central nervous system. The company competes in the neurodegenerative disease space where larger pharmaceutical companies and emerging biotechs are developing disease-modifying treatments for Alzheimer's, Parkinson's, and Lewy body diseases.

Industry Context

Cognition Therapeutics Inc operates in Pharmaceuticals.

Key facts

Founded: 2007 · Headquarters: Pittsburgh, US · Employees: 25 · Revenue: N/A · Market cap: $95.34M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cognition Therapeutics Inc.

  • Zervimesine is aimed at addressing psychosis in patients suffering from dementia with Lewy bodies, a condition affecting up to 75% of those diagnosed with the disease.
  • The company conducted a planned FDA meeting on May 20, 2026, to review Phase 2 results, with a fully funded $80 million Phase 2 START trial readout expected in the second half of 2027.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Received final minutes from FDA meeting on zervimesine for dementia with Lewy bodies psychosis
  • April 2026Announced decision to prioritize zervimesine (CT1812) development for DLB psychosis
  • +1 moreTrack every material event for Cognition Therapeutics Inc as it happens. Explore monitoring →
Get alerted when Cognition Therapeutics Inc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LecanemabAnti-amyloid monoclonal antibody for Alzheimer's disease→DonanemabAnti-tau monoclonal antibody for Alzheimer's disease→AducanumabAnti-amyloid monoclonal antibody program→

Compare Cognition Therapeutics Inc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cognition Therapeutics Inc operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Cognition Therapeutics Inc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cognition Therapeutics Inc and its top competitor on Cyborg Score”
“What did Cognition Therapeutics Inc do this quarter?”
“Is Cognition Therapeutics Inc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cognition Therapeutics Inc do?+
Cognition Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and neurocognitive disorders, headquartered in Pittsburgh, Pennsylvania and foun...
What is Cognition Therapeutics Inc's Cyborg Score?+
Cognition Therapeutics Inc has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cognition Therapeutics Inc's main competitors?+
Named competitors include Lecanemab, Donanemab, Aducanumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Cognition Therapeutics Inc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cognition Therapeutics Inc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cognition Therapeutics Inc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.